UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                  June 5, 2006
                Date of Report (Date of earliest event reported)

--------------------------------------------------------------------------------
                                 ANTIGENICS INC
             (Exact name of registrant as specified in its charter)

--------------------------------------------------------------------------------
          DELAWARE                    000-29089                   06-1562417
(State or other jurisdiction         (Commission                (IRS Employer
      of incorporation)              File Number)            Identification No.)

         630 Fifth Avenue, Suite 2100
              New York, NY 10111                                    10111
   (Address of principal executive offices)                      (Zip Code)

                                  212-994-8200
              (Registrant's telephone number, including area code)

--------------------------------------------------------------------------------


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))





Item 7.01   Regulation FD Disclosure

          On June 5, 2006, Antigenics Inc. announced updated findings from its
          Phase 3 clinical trial of the company's investigational cancer vaccine
          Oncophage(R) (vitespen; formerly HSPPC-96) in metastatic melanoma. The
          full text of the press release issued in connection with the
          announcement is being furnished as Exhibit 99.1 to this current report
          on Form 8-K.


Item 9.01   Financial Statements and Exhibits

         (d) Exhibits

         The following exhibit is furnished herewith:

                  99.1     Press Release dated June 5, 2006





                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            ANTIGENICS INC.

Date: June 5, 2006
                                        By: /s/ Garo H. Armen, Ph.D.
                                            ------------------------------------
                                            Garo H. Armen, Ph.D.
                                            Chairman and Chief Executive Officer





EXHIBIT INDEX

Exhibit No.       Description of Exhibit
-----------       ----------------------

99.1              Press Release dated June 5, 2006